New Paradigms in Hypertrophic Cardiomyopathy Care Gameshow Challenge

Cardiac Myosin Inhibition

  • Friday, September 27, 2024
  • 8:00 pm - 9:30 pm ET
  • Triumph E Atlanta
  • Signia Hotel Atlanta | Atlanta, Georgia
  • CME/CNE/CPE
  • Hybrid
Overview


This satellite symposium, held in conjunction with the 2024 Heart Failure Society of America (HFSA) Annual Meeting, has been indefinitely postponed due to the current forecast for the Atlanta, Georgia area. This cancellation includes the virtual program.

We will reach out to all registered attendees to confirm the new event date as soon as possible. We appreciate your patience and understanding and we look forward to seeing you at another Medscape event in the near future.

Speakers
Speaker Image
Sara Saberi, MD, MS
Chairperson

Associate Professor

Co-Director, Inherited Cardiomyopathy Program

Frankel Cardiovascular Center

University of Michigan Hospital, Michigan Medicine

Ann Arbor, Michigan

Speaker Image
Gregory D. Lewis, MD

Professor of Medicine

Harvard Medical School

Section Head, Heart Failure

Director, Cardiopulmonary Exercise Testing Laboratory

Medical Director, Cardiac Transplantation Program

Mass General Hospital

Boston, Massachusetts

Speaker Image
Martin S Maron, MD

Director

Hypertrophic Cardiomyopathy Center

Lahey Hospital & Medical Center

Burlington, Massachusetts

Agenda

Welcome and Introductions

Chairperson, Sara Saberi, MD, MS

HCM Game Show:


  • Round 1 - HCM: Where Are We in 2024?

  • Round 2 - Clinical Updates in HCM: Pearls for Cardiology Practice

  • Round 3 - Case Consults: Integrating New Approaches

Panel Discussion and Q&A

159 Northside Dr NW, , Room: Triumph E Atlanta, Georgia, 30313
Get Directions
Program Information
Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Accreditation logos
Accreditation logos
For Physicians

Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.

For Pharmacists

Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-24-215-L01-P).

Learning Objectives

Upon completion of this activity, participants will:

Have increased knowledge regarding the:

  • Unmet clinical needs of patients with HCM
  • Mechanism of action (MOA) of CMIs to target the underlying pathology of HCM
  • Recent clinical trial data for emerging HCM therapies

Have greater competence related to

  • Identification of patients with HCM who may benefit from CMI therapy

Demonstrate greater confidence in their ability to

  • Integrate CMIs into treatment plans for appropriate patients
Goal Statement
The goal of this activity is for learners to be better able to discuss and evaluate the mechanistic rationale and latest clinical data for the use of CMI therapy in the evolving treatment landscape for HCM.
Target Audience
This activity is intended for cardiologists, primary care physicians, emergency medicine physicians, diabetologists/endocrinologists, nurse practitioners, nurses, physician assistants, and pharmacists.

Supported by an independent educational grant from Cytokinetics.